Quantum Labs
简体中文
CJC-1295 + Ipamorelin 5 mg + 5 mg10 瓶装库存 6立省 22%
精选peptideintermediate库存 6

CJC-1295 + Ipamorelin 5 mg + 5 mg

经典 GHRH + 胃饥饿素模拟物组合

CJC-1295 and Ipamorelin research stack, Australian-shipped. Lab-verified to ≥99% purity.

剂量
5mg + 5mg / 瓶
剂型
冻干粉末
包装
10 瓶装

仅供研究使用。 本化合物严格用于体外研究及实验室用途,不得用于人体食用或治疗用途。购买即确认您为合格研究者,并同意我们的 完整免责声明。

¥1,432 CNY
立省 22%
10 瓶装
原价 ¥1,834 CNY
以 10 瓶装出售

仅剩 6 盒

🧪实验室验证
✓第三方检测
⚡全球快速配送
🔒安全银行卡支付
概览

将 CJC-1295(GHRH 类似物)与选择性胃饥饿素模拟物 Ipamorelin 配于同一研究用瓶。肽研究中最常被研究的双机制 GH 促分泌组合。

CJC-1295 and Ipamorelin are a long-standing pair in growth-hormone secretagogue research. CJC-1295 is a 30-amino-acid analogue of growth-hormone-releasing hormone (GHRH); Ipamorelin is a selective ghrelin receptor agonist (a 'GHS' or growth-hormone secretagogue). The two compounds act on different receptors but converge on the somatotrophs of the anterior pituitary, where they amplify pulsatile growth-hormone release in pre-clinical models.

Quantum Labs supplies the pair as a pre-portioned research stack — two lyophilised vials shipped together, each HPLC-verified to ≥99% purity. Australian-shipped from local stock; supplied for laboratory research use only.

作用机制

CJC-1295 支持基础 GHRH 受体信号,Ipamorelin 驱动选择性胃饥饿素受体脉冲。研究提示在受试对象中产生协同、接近生理节律的 GH 释放模式。

实验室报告

经 HPLC 验证,纯度规格 ≥99%。由获认可的第三方实验室独立检测。

CJC-1295: DAC vs no-DAC

CJC-1295 exists in two research forms: with Drug Affinity Complex (DAC) and without. The DAC variant binds albumin in plasma, extending the half-life from minutes to days. Research designs targeting acute pulsatile GH release typically use the no-DAC form (modified GRF 1-29); studies modelling sustained GH elevation use the DAC variant. Our supply is the no-DAC research-grade form unless otherwise specified.

研究者常见问题

CJC-1295 + Ipamorelin — 常见问题

What is the CJC-1295 + Ipamorelin stack?

It is a research pairing of two growth-hormone secretagogues: CJC-1295 (a GHRH analogue) and Ipamorelin (a selective ghrelin receptor agonist). The two compounds act on different receptors but converge on stimulating pulsatile growth-hormone release in pre-clinical models.

How does CJC-1295 differ from Ipamorelin?

CJC-1295 mimics growth-hormone-releasing hormone (GHRH), binding the GHRH receptor on pituitary somatotrophs. Ipamorelin mimics ghrelin, binding the growth-hormone secretagogue receptor (GHSR-1a). The two pathways are independent but synergistic — combining them produces a larger pulsatile GH response in research models than either compound alone.

Is CJC-1295 + Ipamorelin legal in Australia?

Both compounds are restricted for human therapeutic supply in Australia and remain available for research and laboratory use when supplied without therapeutic representation. Quantum Labs supplies the stack for research use only.

What does selective mean for Ipamorelin?

Ipamorelin is described as a selective ghrelin agonist because it activates the GH-release pathway with minimal effect on cortisol, prolactin, or aldosterone — distinguishing it from earlier-generation GHS molecules. This selectivity has made it a preferred research tool for isolating GH-specific effects.

What is the typical CJC-1295 + Ipamorelin research dosage?

Published research protocols have used wide dose ranges depending on the model and species. Human dosing is not established. Researchers should consult primary literature for protocol-specific guidance.

Are CJC-1295 and Ipamorelin used together?

Yes — combined-administration research is common precisely because the two compounds act on independent receptors and produce a synergistic GH-release response. The combination is a standard tool in growth-hormone secretagogue research.

延伸阅读

与 CJC-1295 + Ipamorelin 相关的指南

相关化合物

研究者还会浏览